Kelly S. Chien

Ponatinib and blinatumomab for Philadelphia chromosome-positive acute lymphoblastic leukaemia: a US, single-centre, single-arm, phase 2 trial

Elias Jabbour, Nicholas J. Short, Nitin Jain et al. · The Lancet Haematology · 2022 · 239 citations

Medicine, Hematology, Oncology +12

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory <i>FLT3</i>-Mutated AML

Nicholas J. Short, Naval Daver, Courtney D. DiNardo et al. · Journal of Clinical Oncology · 2024 · 146 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +15

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Christopher B. Benton et al. · Blood Advances · 2020 · 132 citations · Full text

Life Sciences, Genetics, Hematology +17

High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance

Hui Yang, Guillermo Garcia‐Manero, Koji Sasaki et al. · Leukemia · 2022 · 95 citations · Full text

Life Sciences, Genetics, Molecular Genetics +17

Azacitidine plus venetoclax in patients with high-risk myelodysplastic syndromes or chronic myelomonocytic leukaemia: phase 1 results of a single-centre, dose-escalation, dose-expansion, phase 1–2 study

Alexandre Bazinet, Faezeh Darbaniyan, Elias Jabbour et al. · The Lancet Haematology · 2022 · 82 citations

Medicine, Pharmacology, Pharmacotherapy +15